Forge Ahead with a New Chapter: Nuance Pharma Beijing Headquarters Grand Opening Ceremony Celebrated in Changping

May 8, 2026, Beijing – Nuance Pharma officially held its Beijing Headquarters and R&D Center grand opening ceremony at the Astrobridge Changping International Life Sciences Park in Changping District, Beijing. This marks a new chapter for Nuance Pharma in China and demonstrates the company’s firm commitment to establishing deep roots in Changping while focusing on key therapeutic areas including respiratory diseases, iron deficiency anemia, and emergency care.

Pictured from left to right: Edward Li, Zhao Shiwei, Mark Lotter, and Dr. Andreas Amrein

The ceremony, themed “Forge Ahead,” was attended by a distinguished group of guests. Attendees included Mr. Zhao Shiwei, Deputy Director of the Future Science City Administrative Committee and Deputy Mayor of Changping District; Mr. Edward Li, Chief Operating Officer of CBC Group; Mr. Su Zhiqiang, Managing Director of Beijing Shunxi Private Equity Fund Management Co., Ltd.; Ms. Xie Sijin, Senior Vice President of Beijing Changping Technology Innodevelop Industry Operation & Management Co., Ltd.; Mr. Liu Xiaohan, Chief Financial Officer of Konruns Pharmaceutical Co., Ltd.; Director appointed by CRHC Fund Management Co., Ltd.; as well as Mr. Mark Lotter, Founder and CEO of Nuance Pharma, and Dr. Andreas Amrein, CEO and Chairman of the Board of global partner Stallergenes Greer, among others, who delivered speeches at the event.

Government Message: Nurturing the Innovation Ecosystem to Build a High-Industry Hub

Zhao Shiwei, Deputy Director of the Future Science City Administrative Committee and Deputy Mayor of Changping District, said:” Nuance Pharma is a high-quality enterprise that Changping District has prioritized for attraction and cultivation. The establishment of its Beijing headquarters will inject strong momentum into the district’s efforts to strengthen leading industries and cultivate new productive forces.” He noted that Changping District has gathered over 2,900 pharmaceutical and healthcare enterprises, forming a full-chain ecosystem from laboratory to industrialization. Changping District will continue to optimize the business environment and work hand in hand with enterprises.

Company Outlook: Focusing on Unmet Needs, Building a Specialty Pharma Benchmark in Asia-Pacific

Mark Lotter, founder and Chief Executive Officer of Nuance Pharma, reviewed the company’s journey in his speech. He highlighted that Nuance Pharma is focused on the respiratory disease area and has built a portfolio of highly promising assets, including the first inhaled therapy Ensifentrine (Ohtuvayre®) for maintenance treatment of COPD in adults, for which an NDA has been submitted to the NMPA; allergy and immunology products in collaboration with Stallergenes Greer; and innovative therapies for respiratory distress syndrome.

Mark Lotter emphasized: “Today’s opening is not just the inauguration of an office; it is a demonstration of our long-term commitment to innovation and growth. We strive to build Nuance into a platform where ideas are transformed into solutions and collaboration inspires innovation, continuously bringing breakthrough therapies to patients in China and the broader Asia-Pacific region.”

 Capital Empowerment: Long-term Partnership to Fuel Value Creation

Edward Li, Chief Operating Officer of CBC Group, said that CBC Group has always focused on and empowered Nuance Pharma throughout its full-cycle development, from critical milestones to industrial space. He stated that going forward, CBC Group will join hands with BEIJING CHANGPING Technology Innodevelop Group (CTID), and with the support of the Changping District Government, leverage the Astrobridge Changping International Life Sciences Park as a core hub, using capital as a bridge, industry as the foundation, and the ecosystem as a backbone, to attract more leading healthcare enterprises to Beijing.

Su Zhiqiang, Managing Director of Beijing Shunxi Private Equity Fund Management Co., Ltd., said that Nuance Pharma adheres to a dual-engine model of “R&D + Commercialization,” forming differentiated core competitiveness in areas such as oral iron supplementation and COPD. Through this equity investment, Shunxi Fund, together with all partners, has helped Nuance Pharma complete its headquarters relocation and ensure stable migration of its supply chain, enabling core products to take root in Beijing.

Xie Sijin, Senior Vice President of Beijing Changping Technology Innodevelop Industry Operation & Management Co., Ltd., said that Nuance Pharma’s move into the Astrobridge Changping International Life Sciences Park represents a high recognition of CTID’s industrial facilities and service capabilities. In the future, CTID will provide full-cycle support in clinical translation, industry collaboration, policy application, and more, helping Nuance Pharma achieve further pipeline breakthroughs and product commercialization.

Global Collaboration: Innovation Without Borders, A Win-Win New Chapter

Dr. Andreas Amrein, CEO and Chairman of the Board of global partner Stallergenes Greer, said that Stallergenes Greer has more than 120-year history and a presence in 46 countries, but the most important market in the world in number of patients – China – has yet remained untapped by the company. “We are truly honored to be working with Mark Lotter and the Nuance team to bring our treatments to China. Today’s ceremony is not only a milestone for Nuance Pharma but also an important milestone for us.”

About Nuance Pharma

Nuance Pharma is an innovation-focused biopharmaceutical company, with both late-stage clinical pipeline and commercial stage asset portfolio. Focusing on specialty care, Nuance has established a differentiated combination of commercialized assets and innovative pipeline across respiratory, pain management, emergency care and iron deficiency anemia. With the mission to address critical unmet medical needs in Asia Pacific, Nuance deploys the Dual Wheel model that develops a global leading innovative pipeline, while maintaining a self-sustainable commercial operation in both China and Asia as a region. For more information, please visit www.nuancepharma.com.

Forward-looking Statements

This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.